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Chapter  4 
Acute desensitization of 
isoprenaline-mediated inhibition of 
Ca2+-influx in airway smooth muscle 
cells is potentiated by agonist-
induced protein kinase C activation
Mark Boterman 
















It has been shown that patients with asthma have a reduced bronchodilator response to β-
agonists during a severe exacerbation and that chronic β-agonist therapy can diminish the 
efficacy of these drugs.  In the present study, we considered the possibility that a novel 
form of transductional cross-talk, in which contractile agonist-induced protein kinase C 
(PKC) activation enhances homologous β-agonist-induced desensitization, could contribute 
to these effects. In isolated bovine tracheal smooth muscle cells we investigated the effect 
of the specific PKC inhibitor 2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-
yl) maleimide (GF 109203X) on isoprenaline-mediated inhibition of methacholine-induced 
extracellular Ca2+-influx, using the fluorescent dye Fura-2/AM. Single concentrations of 
isoprenaline (1 nM - 10 μM) were administered on the methacholine (100 μM)-induced 
Ca2+-plateau at t = 150 or 340 seconds after methacholine. 
Isoprenaline caused a rapid and transient inhibition of the methacholine-induced Ca2+-
influx at all concentrations of the β-agonist, indicating rapid desensitization of this 
response. This β2-adrenoceptor desensitization was markedly reduced in the presence of GF 
109203X, indicating that methacholine-induced activation of PKC was importantly 
involved.GF 109203X had no significant effect on the isoprenaline-induced peak-inhibition 
of Ca2+-influx and no differences were found between the two different application times of 
isoprenaline (t = 150 or 340 seconds), suggesting that direct heterologous desensitization of 
the β2-adrenoceptor induced by PKC was not involved in the short lasting effect of 
isoprenaline.  
The results indicate that acute β-agonist-induced homologous desensitization of the β2-
adrenoceptor in bovine tracheal smooth muscle cells is markedly amplified by muscarinic 
agonist-induced PKC activation. 
 
Introduction 
Inhaled β2-adrenergic agonists are by far the most effective bronchodilators used to control 
airway function in patients with asthma [1-3]. The efficacy of these drugs is mainly due to 
functional antagonism, counteracting the bronchoconstrictor effects of neurotransmitters 
and mediators released in airway inflammation [4]. However, it is well known that patients 
with asthma have a reduced bronchodilator response to β-agonists during a severe 
exacerbation [5,6]. Moreover, it has been shown that chronic β-agonist therapy can 
diminish the efficacy of these drugs [7,8], resulting in a loss of bronchoprotection against 
contractile stimuli and allergens [9]. 
Several protein kinases, including G protein-coupled receptor kinases (GRKs), protein 
kinase A (PKA) and protein kinase C (PKC) have been implicated in modulating β2-
adrenoceptor function. Homologous desensitization of the β2-adrenoceptor is mediated by 
activation of GRKs. GRKs phosphorylate the agonist-occupied form of the receptor, after 
translocation to the plasma membrane by anchoring to free Gβγ subunits generated upon 
receptor activation. This  results in binding of β-arrestins and subsequent uncoupling of the 
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receptor from its stimulatory G protein (Gs), which is followed by sequestration and/or 
downregulation of the receptor [10,11]. The GRK family consists of seven isoforms that 
share a number of structural and functional similarities and GRKs 1-6 have been shown to 
phosphorylate the β2-adrenoceptor in its C-terminal cytoplasmatic tail [12,13].  
Another possible mechanism of reduced β2-adrenoceptor function is heterologous 
desensitization, which may be induced by PKC and PKA. Agents which activate PKC, 
including muscarinic agonists and phorbol esters, have been shown to attenuate β-agonist-
induced cAMP accumulation in airway smooth muscle slices [14], presumably involving 
phosphorylation of the third intracellular loop of the β2-adrenoceptor and subsequent 
uncoupling from Gs [15]. Recently, we have presented direct functional evidence for the 
involvement of PKC in the cross-talk between muscarinic M3 receptor stimulation and β2-
adrenoceptor-induced relaxation in bovine tracheal smooth muscle [16] and rat oesophagus 
smooth muscle [17]. PKA, which is activated by agents that increase intracellular cAMP 
levels, has also been identified as an important mediator of heterologous desensitization by 
phosphorylating the β2-adrenoceptor in the third intracellular loop [10,18,19].  
Interestingly, some studies have indicated that homologous and heterologous 
desensitization are not completely independent processes. Thus, in mononuclear 
leukocytes, it has been shown that activation of PKA and PKC can induce changes in the 
cellular expression and activity of GRKs and β-arrestins [20]. Moreover, it has been 
demonstrated that PKC-induced phosphorylation increased the activity of GRK2 by 
targeting the kinase to the plasma membrane [21]. Importantly, this novel form of cross-talk 
could contribute to the reduced bronchodilator response to β-agonists in patients with 
asthma during a severe exacerbation. We have recently demonstrated that PKC-activation 
by the phorbol ester PMA (phorbol 12-myristate 13-acetate) indeed enhances β-agonist-
induced desensitization of bovine tracheal smooth muscle relaxation by isoprenaline [22]. 
In the present study we explored this concept into further detail at the level of intracellular 
Ca2+-homeostasis in enzymatically dispersed bovine tracheal smooth muscle cells. 
Investigating the effect of the specific PKC-inhibitor GF 109203X on the inhibition by 
isoprenaline of methacholine-induced Ca2+-influx, the present study revealed that the acute 
homologous β2-adrenoceptor desensitization is being amplified heterologously by PKC. 
Therefore, this finding may represent a novel target for therapeutic strategy in patients with 
asthma. 
 
Materials and methods 
Tissue preparation 
Fresh bovine tracheas were obtained from the slaughterhouse and were transported to the 
laboratory within 30 min at room temperature in Krebs-Henseleit (KH) buffer of the 
following composition (nM): NaCl 177.5, KCl 5.6, MgSO4 1.2, CaCl2 2.5, NaH2PO4 1.3, 
NaHCO3 25.0, glucose 5.5, pregassed with 95% O2 and 5% CO2; pH 7.4. The tracheal 




tissue in KH buffer gassed with 95% O2/5% CO2  at room temperature. Subsequently, the 
tracheal smooth muscle was chopped, using a McIlwain tissue chopper, two times at the 
size of 300 μm and three times at 100 μm. Tissue fragments were washed under sterile 
conditions (three times) and maintained overnight in Dulbecco’s modified Eagle’s medium 
(DMEM; 2.5 mg/ml) supplemented with 10 mM NaHCO3, 20 mM HEPES, 100 U/ml 
penicillin, 100 μg/ml streptomycin and 10% fetal bovine serum (FBS) at 37° (55 rpm). 
 
Isolation of tracheal smooth muscle cells 
Tissue fragments were washed three times in Krebs-Ringer-Henseleit (KRH) buffer 
containing (mM); NaCl 125.0, KCL 6.0, MgCl2 2.5, CaCl2 1.2, NaH2PO4 1.2, NaHCO3 
25.0, glucose 11.0, HEPES 25.0, pH 7.4, supplemented with 2.0 mM (±)-dithiothreitol 
(DTT) and were then resuspended in a digestion mixture of  collagenase P (0.75 mg/ml), 
papain (1 mg/ml) and trypsin inhibitor (1 mg/ml) in KRH buffer. The suspension was 
incubated for 20 min at 37°C (55 rpm) and then gently dispersed with a wide-bored pipette. 
After another 10 min of incubation at 37°C (70 rpm), the suspension was gently dispersed 
again and filtered over a 50 μm gauze and the cells were collected by centrifugation 
(1000g, 10 min). The isolated cells were washed three times with KRH, pH 7.4, 
supplemented with 2 mg ml-1 fetal bovine serum (KRH/FBS) and were allowed to 
regenerate for 1h at 37°C (55 rpm). Subsequently, the cells were incubated with the 
fluorescent dye, Fura-2/AM (3 μM) for 30 min at 37°C (55 rpm). The loaded cells were 
washed three times in KRH/FBS and resuspended to a density of 1 x 106 cells/ml. The cells 
were kept at room temperature on a Rock-N-Roller (Breda Scientific, The Netherlands) and 
used within 2-4 h, during which they remained viable and responsive. 
 
Intracellular Ca2+ measurements 
Fura-2 fluorescence of the cells (excitation wavelengths: 340 and 380 nm; emission 
wavelength: 510 nm) was measured at 37°C with a Perkin Elmer Spectrometer (LS-50B). 
Each cuvet contained 2 ml of magnetically stirred cell suspension. In all experiments, Ca2+-
influx and -mobilisation was induced by 100 μM methacholine, added at t = 0 s. To 
establish the inhibitory effect of isoprenaline on Ca2+-influx, single doses of isoprenaline (1 
nM – 10 μM) were administered on the methacholine-induced sustained rise in intracellular 
Ca2+ concentration (Ca2+-plateau) at t = 150 or 340 s. When used, GF109203X (10 μM) was 
added 45 min prior to the methacholine administration. The intracellular Ca2+-concentration 
([Ca2+]i) was calculated every 0.2 s according to Grynkiewicz [23]. At the end of the 
experiment, the maximal fluorescence ratio (Rmax) was determined after adding 0.01% of 
Triton-X-100 as a permeabilizing agent. The minimal fluorescence ratio (Rmin) was 
determined by addition of 5 mM EGTA to the permeabilized cells. 
 




The methacholine-induced transient rise of [Ca2+]i, representing Ca2+-mobilisation from 
internal stores, was expressed as the maximal increase of [Ca2+]i above basal after the 
addition of  methacholine. The plateau level of [Ca2+]i, representing Ca2+-influx, was 
expressed as the value obtained 2 min after contractile agonist addition.  
The acute inhibitory effect of isoprenaline was expressed as the peak-inhibition of [Ca2+]-
influx immediately after the administration of isoprenaline. The inhibitory effect of  
isoprenaline on the methacholine-induced Ca2+-plateau was also expressed as the area 
under the [Ca2+]i-time curve above basal during 190 s after the addition of isoprenaline 
(AUC150-340 and AUC340-530), calculated by trapezoid integration over 0.2 s periods, 
compared to control in the absence of the β-agonist. Due to isoprenaline-induced 
desensitization, this inhibition was time-dependently reversed. The rate of this Ca2+-influx 
reversal was expressed as its maximal slope. All data are presented as means ± S.E.M. 
Statistical analysis was performed by means of the two-tailed Student’s t-test for paired 
observations. P values < 0.05 were considered statistically significant. 
 
Materials 
Dulbecco’s modification of Eagle’s Medium (DMEM), NaHCO3 solution (7.5%), 
penicillin/streptomycin solution (5000 U/ml ; 5000 μg/ml) and HEPES solution (1 M) were 
obtained from Gibco BRL Life Technologies (Paisley, U.K.). Fetal bovine serum (FBS), 
dithiothreitol (DTT), trypsin inhibitor (type II-S), Fura-2/AM, methacholine chloride and (-
)-isoprenaline hydrochloride were obtained from Sigma Chemical Co. (St. Louis, MO, 
U.S.A.) and GF 109203X (2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl) 
maleimide), papain and Collagenase P were purchased from Boehringer (Mannheim, 
Germany). All other chemicals were of analytical grade. 
 
Results 
Figure 1a shows a typical intracellular Ca2+-response in bovine tracheal smooth muscle 
cells to 100 μM methacholine, characterised by a transient-rise in [Ca2+]i, followed by a 
sustained plateau level of [Ca2+]i. As is also demonstrated in this figure, 10 μM isoprenaline 
caused a rapid but short-lasting inhibition of the methacholine-induced Ca2+-plateau, which 
was almost fully reversed at t = 340 s, i.e. 190 s after β-agonist administration, indicating a 
rapid desensitization of the isoprenaline-induced response.  
In the presence of GF 109203X, basal Ca2+ level as well as the methacholine-induced 
transient and the sustained rise in [Ca2+]i were slightly inhibited (Fig. 1b and 2). 
Remarkably, the isoprenaline-induced inhibition of [Ca2+]i-influx was only partially 
reversed at t = 340 s in the presence of the PKC-inhibitor (Fig. 1b), indicating that GF 
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Figure 1 Typical intracellular Ca2+-responses in bovine tracheal smooth muscle cells, showing the effect of 10 
μM (-)-isoprenaline (Iso) on 100 μM methacholine (MCh)-induced Ca2+-plateau in the absence (a) and presence 




















Using the AUC150-340 as a parameter, it is demonstrated in Figure 3 that isoprenaline dose-
dependently inhibited the methacholine-induced Ca2+-plateau, which was significantly 
potentiated by GF 109203X. Maximal (Emax) values of isoprenaline-induced inhibition of 
Figure 2 Effect of 10 μM GF 109203X on
basal Ca2+-level (A) and the 100 μM
methacholine-induced peak-rise in Ca2+ (B)
and subsequent Ca2+-plateau (C) in bovine
tracheal smooth muscle cells. Results are
means ± S.E.M. of 6 experiments.
Significantly different from control:  
* P<0.05; ** P<0.01 






















10 µM GF 109203X
Ca2+-influx in the absence and presence of GF 109203X were 34.5 ± 7.6% and 66.3 ± 
5.0%, respectively (P = 0.02). No differences were found in the potency of isoprenaline 





















The difference in Emax of the isoprenaline-induced inhibition of Ca2+-influx, using the 
AUC150-340 as a parameter, may well be explained by the different recovery rates of this 
inhibition in the absence and presence of GF 109203X. Figure 4 shows that, after an initial 
rise at 10 nM, compared to 1 nM isoprenaline, the rate of recovery decreased dose-
dependently, both in the presence as well as in the absence of GF 109203X. For all 
isoprenaline concentrations used, GF 109203X significantly reduced this rate of recovery 
compared to control, resulting in a beneficial effect on the isoprenaline-induced inhibition 
of [Ca2+]i-influx. Interestingly,  from 10 nM isoprenaline on, the fractional reduction by GF 
109203X on the rate of recovery increased with higher concentrations of the β-agonist.  
We also investigated the effect of GF 109203X on the maximal inhibition of the Ca2+-
influx, immediately after administration of the β-agonist (Fig. 5). This effect was 
concentration-dependent and maximal at 10-7 M isoprenaline. Interestingly, GF 109203X 
had only a minor effect on this peak-inhibition; Emax values in the absence and presence of 
GF 109203X were not significantly different (85.5 ± 4.5 and 101.6 ± 5.9, respectively; P = 
0.09). No significant differences were found in the potency of isoprenaline (pEC50  values 
of 8.7 ± 0.2 and 8.5 ± 0.1 in the absence and presence of GF 109203X, respectively). 
 
Figure 3 Effect of (-)-isoprenaline on 100
μM methacholine-induced Ca2+-plateau,
measured as AUC150-340, compared to control,
in the absence (open symbols) and presence
(closed symbols) of 10 μM GF 109203X in
bovine tracheal smooth muscle cells. Results



























































































To assess the role of methacholine-induced PKC activation in heterologous desensitization 
of the β2-adrenoceptor, independent of its effect on the acute β-agonist induced 
desensitization, we compared two different application times of isoprenaline. If a direct 
interaction of activated PKC with the β2-adrenoceptor would be responsible for the 
observed desensitization of the isoprenaline-induced inhibition of Ca2+-influx, this would 
imply that isoprenaline could hardly or not be able to exert an effect anymore when added 
at 340 s instead of at 150 s.  
Figure 4 Effect of 10 μM GF 109203X on
the recovery of isoprenaline-induced Ca2+-
influx inhibition. The rate of [Ca2+]i-recovery
(nM/s) was expressed as its maximal slope.
Results are means ± S.E.M. of 6 experiments.
Significantly different from control: * P<0.05;
** P<0.01; *** P<0.001 
Figure 5 Effect of (-)-isoprenaline on 100
μM methacholine-induced Ca2+-plateau,
measured as maximal inhibition of [Ca2+]i
immediately after administration of the β-
agonist, in the absence (open symbols) and
presence (closed symbols) of 10 μM GF
109203X. Results are means ± S.E.M. of 6
experiments. 





























Figure 6 Typical intracellular Ca2+-responses, showing the effects of 10 μM (-)-isoprenaline added at t = 150 s 
(a) or 340 s (b) on 100 μM methacholine-induced Ca2+-plateau, in the absence (upper panels) and presence (lower 
panels) of 10 μM GF 109203X. 
 
Typical Ca2+-responses, showing the effects of 10 μM isoprenaline added at t = 150 s and 
340 s on the methacholine-induced Ca2+-plateau, as presented in Figure 6, show identical 
peak-inhibition at the two time points, irrespective of the presence of GF109203X. Using 
the AUC150-340 and AUC340-530, we also found almost identical effects of isoprenaline, both 
in the presence and absence of GF 109203X (Fig. 7). Similar results were obtained for 1 
and 10 μM isoprenaline (Fig. 7). Moreover, no differences were found in the immediate 
inhibitory effects of isoprenaline (1 and 10 μM) at t = 150 s and t = 340 s (not shown). 
 























































































The present study indicates that muscarinic agonist-induced PKC activation markedly 
contributes to β-agonist induced β2-adrenoceptor desensitization in bovine tracheal smooth 
muscle cells. Thus, it was shown that isoprenaline caused a transient inhibition of the 
methacholine-induced Ca2+-influx, indicating a rapid agonist-induced desensitization of this 
response. This β2-adrenoceptor desensitization was markedly attenuated in the presence of 
the PKC-inhibitor GF 109203X, indicating major involvement of methacholine-induced 
activation of PKC, following phosphoinositide metabolism and generation of 
diacylglycerol.  
The heterologous regulation of β-agonist induced desensitization by PKC might involve 
phosphorylation-induced activation of GRK2. Thus, in mononuclear leukocytes it has been 
found that PKC-dependent increase in GRK2 activity enhanced the isoprenaline-induced 
homologous β2-adrenoceptor desensitization [20]. In addition, it has been shown that GRK2 
activity indeed can be increased by PKC-induced phosphorylation, possibly by increasing 
the ability of GRK2 to bind to the plasma membrane [21,24] or by relieving tonic inhibition 
of GRK2 by calmodulin, allowing GRK2 to bind to the β-adrenoceptor [25]. Not only 
GRK2 but also GRK5 has been shown to be a substrate for PKC. However, in contrast to 
GRK2, PKC-induced phosphorylation of GRK5 strongly inhibits its activity [26], 
indicating that this mechanism is not involved in the observed PKC-induced potentiation of 
acute agonist-induced β2-adrenoceptor desensitization. However, irrespective of the 
GRK(s) involved, we very recently demonstrated that direct activation of PKC by the 
phorbol ester PMA potentiates the homologous β-agonist-induced desensitization of intact 
Figure 7 Effect of 1 μM (a) and
10 μM (b) (-)-isoprenaline added at
t = 150 or 340 s on 100 μM
methacholine-induced Ca2+-plateau,
measured as AUC150-340 and
AUC340-530 , compared to control, in
the absence (open bars) and
presence (filled bars) of 10 μM GF
109203X. Results are means ±
S.E.M. of 4 separate experiments.
Significantly different from control:
* P<0.05; *** P<0.001. 
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bovine tracheal smooth muscle relaxation by isoprenaline [22]. Presently it is unclear which 
PKC-isozyme is involved in the modulation of β2-adrenoceptor desensitization, since GF 
109203X inhibits all conventional (α, β1 and β2) and novel (δ, ε and θ)  PKC isozymes 
present in bovine tracheal smooth muscle [27].  
Remarkably, a possible direct heterologous effect of methacholine-induced PKC activation 
on β2-adrenoceptor function was only small or even absent at t = 150 s, as indicated by the 
minor effect of GF 109203X on the peak-inhibition of Ca2+-influx immediately after the 
administration of isoprenaline, and by the equal levels of inhibition of Ca2+-influx by 
isoprenaline at different time points after methacholine addition. In contrast, we have 
previously presented direct evidence for the involvement of PKC in the cross-talk between 
muscarinic M3 receptor stimulation and β2-adrenoceptor function, strongly diminishing β-
agonist-induced bovine tracheal smooth muscle relaxation [16]. However, these effects 
were observed after longer incubation times with methacholine, i.e. after establishment of 
tonic contraction. This strongly suggests that PKC-induced activation of GRK(s) is the 
main cause of the rapid β-adrenoceptor homologous desensitization and that this process 
precedes PKC-induced β2-adrenoceptor (and/or Gs) phosphorylation. 
From 10 nM isoprenaline on, the rate of Ca2+-recovery decreased dose-dependently with 
higher concentrations of isoprenaline. Although GRK is particularly activated at high β-
agonist concentrations, the GRK-induced desensitization may be partially overruled by the 
efficacy of the agonist to increase cAMP accumulation inhibiting Ca2+-influx. GF 109203X 
significantly inhibited the rate of recovery for all concentrations of isoprenaline used, which 
is fully in line with the observed effects of GF 109203X on the isoprenaline-induced 
inhibition of Ca2+-influx, using the AUC150-340 as a parameter. Assuming that PKC enhances 
GRK-induced desensitization, this observation is in line with the fact that GRK-induced 
desensitization becomes quantitatively more important at higher concentrations of 
isoprenaline [13,18,28]. 
It was demonstrated that isoprenaline-induced desensitization was not fully reversed by GF 
109203X, indicating PKC-independent contribution of GRKs and/or PKA to the agonist-
induced desensitization. Notably, in previous studies in bovine tracheal and rat oesophagus 
smooth muscle it has been demonstrated that PKA-dependent, but β-adrenoceptor-
independent, relaxation induced by forskolin and  3-isobutyl-1-methyl-xanthine (IBMX) 
was not inhibited by 10 μM GF109203X [16,17], indicating that PKA-activity is not 
affected by the PKC inhibitor. As shown in Figures 1 and 2, GF 109203X slightly 
diminished both the methacholine-induced Ca2+-transient and the Ca2+-plateau, which is in 
agreement with previous observations indicating that methacholine-induced PKC activation 
may potentiate agonist-induced mobilization and influx of Ca2+ in bovine tracheal smooth 
muscle cells [29]. This effect is relatively small at high concentrations of methacholine 
[29], hence all experiments were performed with 100 μM of the agonist.  
In conclusion, the present study was undertaken to explore the concept of heterologous 
regulation of homologous β2-adrenoceptor desensitization by contractile agonists in airway 
smooth muscle cells. The results indicated that methacholine-induced PKC-activity is 




of Ca2+-influx in bovine tracheal smooth muscle. Since it was demonstrated that direct 
heterologous desensitization of the β2-adrenoceptor by PKC was hardly or not involved 
under the conditions used, muscarinic receptor-mediated PKC-activation may indeed 
potentiate the β-agonist-induced (homologous) desensitization, presumably by enhancing 
GRK activity. As many PKC-activating mediators and neurotransmitters are being released 
during an asthma exacerbation, the cross-talk between PKC and GRKs may be of great 
functional importance for the development of a β2-adrenoceptor dysfunction in patients 
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